◀ All Modalities

Biologic Modality

Wharton’s Jelly
WJ-MSCs

Umbilical cord-derived mesenchymal stem cells with the highest MSC density of any perinatal tissue source. Rich in collagen I, III and V, long-chain hyaluronic acid, and 60+ growth factors that work together to modulate inflammation, stimulate tissue repair, and support regeneration across multiple specialties.

Orthopedics Neurology Aesthetics Wound healing Anti-inflammatory Allogeneic
Request Information View Research
60+
Growth Factors
#1
Highest MSC Yield
3
Collagen Types
IRB
Largest in Biologics

How it works

Mechanism of action

Wharton’s Jelly MSCs do not work by directly replacing damaged cells. They work through paracrine signaling — releasing bioactive molecules that instruct your body’s own cells to repair, regenerate, and rebalance.

01
Paracrine Signaling
WJ-MSCs release growth factors, cytokines, and exosomes that signal surrounding cells to reduce inflammation, proliferate, and begin repair processes. The therapeutic effect is primarily indirect — through communication, not engraftment.
02
Immunomodulation
WJ-MSCs express low levels of HLA class II antigens, making them immune-privileged. They actively suppress pro-inflammatory T-cell responses and shift macrophages from M1 (inflammatory) to M2 (repair) phenotype.
03
Structural Matrix Support
The Wharton’s Jelly matrix itself — collagen I, III and V, hyaluronic acid, chondroitin sulfate, and proteoglycans — provides a bioactive scaffold that supports cellular adhesion, migration, and tissue architecture restoration.
04
Angiogenesis
High VEGF and PGF content stimulates formation of new blood vessels at the treatment site, improving oxygen and nutrient delivery to healing tissue — a critical factor in chronic wound and joint repair.
05
Anti-Fibrotic Effects
WJ-MSC secretome suppresses TGF-beta-driven fibrosis pathways, reducing scar tissue formation in joints, tendons, and skin. Clinical studies show measurable reduction in fibrotic markers post-injection.
06
Exosome Release
WJ-MSCs are among the most prolific exosome producers of any MSC source. These nano-vesicles carry miRNA cargo that enters target cells and modulates gene expression — extending the therapeutic effect far beyond the injection site.

Bioactive profile

60+ Growth Factors
Working Together

No single growth factor drives WJ-MSC therapy. The therapeutic effect comes from the full-spectrum paracrine profile — a coordinated signaling cascade that addresses inflammation, repair, and regeneration simultaneously.

TGF-β1
Very high
VEGF
Very high
PDGF-AA
High
IL-1RA
High
IGF-1
Moderate
IGFBPs
Moderate
EGF
Present
HGF
Present
bFGF
Present
PGF
Present

Source: Drobiova et al., Frontiers in Cell & Developmental Biology, 2023

MSC yield by tissue source
Wharton’s Jelly✓ Highest
Adipose tissueHigh / autologous
Bone marrowModerate · invasive
PlacentaModerate
Amniotic fluidLow-moderate
Peripheral bloodVery low
Why WJ over adult sources?

Perinatal tissue is immunologically naive. WJ-MSCs express low HLA class II, making them safe for allogeneic use without immunosuppression.

WJ-MSCs proliferate faster and maintain multipotency for more passages than bone marrow or adipose-derived MSCs.

The matrix itself (collagen, HA, proteoglycans) adds structural therapeutic value beyond the cells alone.

The matrix

What’s in
Wharton’s Jelly

Beyond the MSCs, the extracellular matrix of Wharton’s Jelly is itself a bioactive therapeutic. Each component has independent clinical value.

Collagen Type I
Primary structural protein. Provides tensile strength and scaffold for fibroblast migration during tissue repair. Critical for tendon, ligament, and skin regeneration.
Collagen Type III
Early-phase repair collagen. Predominant in initial wound healing and vascular tissue. Replaced over time by Type I as tissue matures and strengthens.
Collagen Type V
Regulates collagen fibril assembly. Controls the diameter and spacing of collagen bundles — important for the mechanical properties of repaired connective tissue.
Long-Chain Hyaluronic Acid
High-molecular-weight HA provides deep joint lubrication and sustained tissue hydration. Anti-inflammatory at high molecular weights. Supports cartilage matrix integrity.
Chondroitin Sulfate
Structural proteoglycan that supports cartilage matrix, resists compressive forces, and retains water in the extracellular space. Clinically associated with joint symptom relief.
Proteoglycans
Large molecules that bind and regulate growth factors in the matrix, creating a sustained-release depot at the treatment site. Extend the bioactive window of the product beyond initial injection.

Where it works

Clinical Applications

WJ-MSCs are among the most versatile biologics available. Their combination of immunomodulation, structural matrix, and growth factor profile makes them effective across a wide range of specialties.

🧎
Joint Pain & OA
Intra-articular · Cartilage support · IL-1RA
 🦴
Spine & Disc
Disc regeneration · Anti-fibrotic · Neuro support
 🧠
Neurological
TBI · Dementia · Parkinson’s · MS · Stroke
 ✨
Aesthetics
Skin rejuvenation · Anti-aging · Collagen support
 💪
Tendon & Ligament
Rotator cuff · ACL · Tendinopathy
 🩹
Wound Healing
Diabetic ulcers · Chronic wounds · Anti-fibrotic
 ⚽
Sports Medicine
Recovery · Cartilage · Soft tissue repair
 🤰
Reproductive
Endometrial repair · Emerging applications

Evidence base

Peer-reviewed research on
Wharton’s Jelly MSCs

Selected from PubMed, PMC, Frontiers, and ClinicalTrials.gov. Covering neurological, orthopedic, and regenerative applications.

Review
Wharton’s Jelly MSC secretome: clinical applications in immunomodulation, tissue repair, and anti-fibrotic effects
Frontiers in Cell & Developmental Biology · 2023 · Drobiova et al. · Comprehensive secretome analysis covering growth factor profiles, anti-inflammatory mechanisms, and clinical translation
 Review
Characteristics and clinical applications of Wharton’s Jelly-derived MSCs: neurological, hepatic, and orthopedic applications
ScienceDirect · 2019 · Foundational WJ-MSC review covering cell biology, isolation methods, and multi-specialty clinical evidence
 Clinical trial
Mechanically engineered UCMSC-derived exosomes vs. conventional exosomes and PRP for endometrial injury repair
ClinicalTrials.gov · NCT06896747 · Active enrolling · Compares WJ-derived exosome preparations to PRP for reproductive applications
 Review
Biologics for bone and soft tissue regeneration: PRP, BMAC, adipose, amniotic, Wharton’s Jelly, and cord blood
Biomedicines (MDPI) · 2024 · Multi-modality comparative review placing WJ-MSCs in context with other biologics across orthopedic and regenerative applications
 Review
Exosome therapy in neurology: TBI, dementia, Parkinson’s disease, multiple sclerosis, and stroke — comprehensive deep dive
OurBiologics Research Series · Volume 2 · 2026 · Case studies and clinical data covering WJ-MSC derived exosomes in six neurological conditions
 Review
Pediatric stem cell and biologics research: exosomes, WJ-MSCs, and Wharton’s Jelly in pediatric regenerative medicine
OurBiologics Research Series · 2026 · Survey of pediatric clinical applications and study findings for umbilical cord-derived biologics

OurBiologics products

Wharton’s Jelly
Product Lines

All products manufactured by Platinum Biologics (Orlando, FL) in ISO Class cleanrooms. GMP compliant. AATB accredited. IRB protected.

Nano Flex
Wharton’s Jelly 150mg or 300mg. MSC matrix, collagen I/III/V, hyaluronic acid. The flagship WJ product.
From $561
Nano Flow
40M MSC growth factors. Highest VEGF & PGF of any allograft on the market. Ideal for vascularization and repair.
From $711
Nano DPM
First lyophilized Wharton’s Jelly at 95mg. No cryogenic storage required. Shelf-stable, point-of-care ready.
$300

Common questions

Questions about
Wharton’s Jelly

Wharton’s Jelly products are regulated as Human Cellular and Tissue-based Products (HCT/Ps) under FDA 21 CFR Part 1271, Section 361. They are not individually FDA-approved for specific indications the way drug products are, but they are FDA-registered, manufactured in GMP-compliant facilities, and must comply with AATB accreditation standards. All OurBiologics WJ products are covered under the largest IRB for biologics in the industry.
WJ-MSCs demonstrate higher proliferative capacity, faster doubling times, and retain multipotency for more passages in culture than adult MSC sources. Critically, they are immunologically privileged due to low HLA class II expression — meaning they can be used allogeneically (from a donor) without immunosuppression. The WJ matrix itself adds structural therapeutic value — collagen, hyaluronic acid, and proteoglycans — that bone marrow or adipose preparations do not provide.
Delivery route depends on the indication. Common routes include intra-articular injection (joints), intradermal or subdermal (aesthetics and skin), intrathecal or IV (neurological applications), and direct tissue injection (tendons, wounds). Your clinical team determines the appropriate protocol based on the specific condition and patient profile.
All Wharton’s Jelly is collected from consenting mothers at healthy full-term deliveries via C-section. Donors undergo full serological screening per FDA and AATB protocols. The umbilical cord is typically discarded after birth — this collection repurposes that tissue under strict ethical and regulatory guidelines. No embryonic tissue is used. No donation is compensated to avoid coercion. The process is reviewed by an independent Institutional Review Board.
Wharton’s Jelly is not a cure and individual outcomes vary. Musculoskeletal applications (joints, tendons, spine) typically show a response window of 4-12 weeks. Neurological applications may require longer observation periods of 3-6 months. Aesthetic applications vary by protocol. Published literature is promising but the evidence base continues to mature. A responsible provider will set realistic expectations before any treatment and monitor outcomes systematically.
Three products in the OurBiologics line are Wharton’s Jelly based: Nano Flex (150mg or 300mg, frozen), Nano Flow (40M MSC growth factors, highest VEGF and PGF on the market), and Nano DPM (95mg lyophilized, shelf-stable, no cold chain required). Nano PRP Jelly is a 70mg WJ product designed specifically for combination with PRP protocols.

Get started

Ready to add Wharton’s Jelly
to your practice?

Give us 10 minutes. We’ll show you the products, the protocols, and what $22,000+ in additional annual revenue looks like for your clinic — completely on us.

Contact Us Now Back to Home
Section 361 HCT/P · AATB Accredited · IRB Protected
Important Regulatory Notice

Wharton’s Jelly products offered through Our Biologics Distributors are human cellular and tissue-based products (HCT/Ps) regulated under FDA 21 CFR Part 1271, Section 361 — not FDA-approved drug products. They are minimally manipulated, intended for homologous use, and manufactured in compliance with AATB accreditation standards and GMP guidelines.

These products have not been evaluated by the FDA for safety or efficacy for any specific indication. They are not intended to diagnose, treat, cure, or prevent any disease. Results may vary. Clinicians are responsible for independent evaluation of suitability for each patient. This material is intended for licensed healthcare professionals only and does not constitute medical advice.

Our Biologics Distributors
© 2026 Our Biologics Distributors · Powered by Platinum Biologics, Orlando, FL.
Products are not FDA approved or licensed to treat, cure, or prevent any disease.